Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC omeprazole

This article was originally published in The Tan Sheet

Executive Summary

Synovics Pharmaceuticals announces March 15 it has entered into a binding letter of intent for exclusive, worldwide rights to the development and commercialization of an OTC omeprazole. Contract processor Fluid Air will deliver the product to Phoenix-based Synovics' subsidiary Kirk Pharmaceuticals. Fluid Air's DuraGran technology will allow Synovics to avoid patent infringement, the firm says. Synovics, formerly known as Bionutrics, bought Kirk in July 2005 (1"The Tan Sheet," Aug. 1, 2005, In Brief). Synovics plans to submit an ANDA in the second half of 2007. Perrigo said in a February analyst call it expects to launch an omeprazole product in November 2008 (2"The Tan Sheet," Feb. 5, 2007, p. 5). Under a licensing agreement, Schering-Plough hopes to bring Santarus' immediate release omeprazole product Zegerid to the market as well (3"The Tan Sheet" Nov. 27, 2006, In Brief)...

You may also be interested in...



Perrigo Foresees 2008 Omeprazole Launch; New Products Offset Sales Woes

Perrigo expects to be able to launch the first store-brand equivalent to Prilosec OTC in November 2008, at the expiration of a 30-month stay

Bionutrics buys Kirk

Phoenix-based supplement and product development firm purchases OTC and generic drug manufacturer Kirk Pharmaceuticals and affiliate Andapharm for $12 mil. in cash and debt, Bionutrics announces July 25. Bionutrics CEO Ronald Lane says the acquisition adds Kirk's "manufacturing and development resources for new OTC drugs employing Bionutrics' proprietary drug technology." Bionutrics is shifting its primary focus from dietary supplement evolvE toward conducting clinical trials for new proprietary supplements "developed to address lipid metabolism and assist in the maintenance of normal cholesterol" slated for launch later this later, according to a June SEC filing...

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel